Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection (BMAC)
Osteoarthritis of the Knee
About this trial
This is an interventional other trial for Osteoarthritis of the Knee
Eligibility Criteria
Inclusion Criteria: Patients between the ages of 18-70 Long standing knee pain from osteoarthritis (KL grade 2-3) despite conventional treatments such as activity modification, weight loss, physical therapy, analgesics, nonsteroidal anti-inflammatory drugs, or injection therapy for at least 6 weeks 7-day average pain score of at least 4 on VAS scale Exclusion Criteria: Systemic diseases (Diabetes, malignancies, infections, etc.) Post-traumatic arthritis Patient had intra-articular injection on affected knee in last three months
Sites / Locations
- Rush University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Other
Autologous (from subject to self) bone marrow aspirate concentrate (BMAC) injections
Corticosteroid injection
Crossover Group
Autologous bone marrow aspirate concentrate (BMAC) will be removed from the subject knee body with a needle, processed and concentrated by an FDA-approved centrifuge (separator) system. The concentrated cells will be injected into the subject knee. "Autologous" means that the subject is receiving back their own cells that were collected.
Corticosteroid injection group (ARM 2) will receive a sham incision.
Any patient in the corticosteroid injection group that shows no improvement in pain after 24 weeks (12 month follow-up if crossover), per physician discretion, will be allowed crossover to the BMAC injection group (ARM 3).